A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2029

Conditions

Cholangiocarcinoma

Interventions

DRUG

Pembrolizumab

Given by IV (vein)

DRUG

Gemcitabine

Given by IV (vein)

DRUG

Cisplatin

Given by IV (vein)

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER